All lobbying filings

CAPITOL COUNSEL LLC

CAPITOL COUNSEL LLC filed a Q2 termination report for AMICUS THERAPEUTICS, INC. on July 16, 2026, reporting $20,000 in lobbying income.

Lobbying for AMICUS THERAPEUTICS, INC. · Biopharmaceutical company.

All filings by CAPITOL COUNSEL LLC · Everything AMICUS THERAPEUTICS, INC. has reported

Filing · LD-2 quarterly report Q2 termination

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 16, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

New Jersey

Representation ended

Apr 15, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Legislative and regulatory issues affecting SMID rare disease biotech companies. FDA approvals of rare diseases.

Medicare/Medicaid

Legislative and regulatory issues affecting SMID rare disease biotech companies.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.